Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-06-19
2007-06-19
Owens, Amelia A. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S035000
Reexamination Certificate
active
10473245
ABSTRACT:
The invention provides kappa receptor agonists of formula (I) and delta receptor antagonists of formula (II), wherein R1–R6X and n have any of the meanings given in the specification, as well as compositions comprising them, methods for their use, and synthetic procedures and intermediates useful for their preparation.
REFERENCES:
patent: 4362870 (1982-12-01), Portoghese
patent: 4401672 (1983-08-01), Portoghese
patent: 4440932 (1984-04-01), Kotick et al.
patent: 4559157 (1985-12-01), Smith et al.
patent: 4608392 (1986-08-01), Jacquet et al.
patent: 4612302 (1986-09-01), Szabo et al.
patent: 4649200 (1987-03-01), Portoghese et al.
patent: 4684620 (1987-08-01), Hruby et al.
patent: 4806556 (1989-02-01), Portoghese
patent: 4816586 (1989-03-01), Portoghese
patent: 4820508 (1989-04-01), Wortzman
patent: 4853371 (1989-08-01), Coy et al.
patent: 4938949 (1990-07-01), Borch et al.
patent: 4992478 (1991-02-01), Geria
patent: 5223507 (1993-06-01), Dappen et al.
patent: 5225417 (1993-07-01), Dappen et al.
patent: 5244904 (1993-09-01), Nagase et al.
patent: 5298622 (1994-03-01), Portoghese et al.
patent: 5332818 (1994-07-01), Nagase et al.
patent: 5352600 (1994-10-01), Gelfand et al.
patent: 5352680 (1994-10-01), Portoghese et al.
patent: 5354863 (1994-10-01), Dappen et al.
patent: 5411965 (1995-05-01), Reid et al.
patent: 5436249 (1995-07-01), Dappen et al.
patent: 5457208 (1995-10-01), Portoghese et al.
patent: 5464841 (1995-11-01), Portoghese et al.
patent: 5578725 (1996-11-01), Portoghese et al.
patent: 5631263 (1997-05-01), Portoghese et al.
patent: 5886001 (1999-03-01), Schmidhammer
patent: 0254545 (1988-01-01), None
patent: 0374756 (1990-06-01), None
patent: 0456833 (1991-11-01), None
patent: WO-9407896 (1994-04-01), None
patent: WO-95/31464 (1995-11-01), None
patent: WO-96/23793 (1996-08-01), None
patent: WO-96/34005 (1996-10-01), None
patent: WO-99/18021 (1999-04-01), None
patent: WO-00/08027 (2000-02-01), None
Lewis, Buprenorphine, (1985), PMID: 2986930.
Bowdle, Adverse effects of opoid agonists and agonist-antagonists in anaesthesia, (1998) PMID:9747665.
Pugsley, Antiarrhythmic effects of U-50,488H in rats subject to coronary artery occlusion, abstract, that teach U-50,488H, a selective kappa receptor agonist has no effect on arrhythmias.(1992).
Abdelhamid, Essam E., et al., “Selective Blockage of Delta Opiod Receptors Prevents the Development of Morphine Tolerance and Dependence in Mice.”,The Journal of Pharmacology and Experimental Therapeutics, 258, (1991),299-303.
Arakawa, K., et al., “The Immunosuppressive Effect of Opioid Receptor Antagonist on Xenogenic Mixed Lymphocyte Reaction.”,Transplantation Proceedings, 24(2), (Apr. 1992),696-697.
Barber, A., et al., “Opiod Agonists and Antagonists: An Evaluation of Their Peripheral Actions in Inflammation”,Medicinal Research Reviews, 12(5), (Sep. 1992),525-562.
Barlow, J. J., et al., “Structure/Activity Studies Related to 2-(3,4-Dichlorophenyl)-N-methyl-N-(2-(1-pyrrolidinyl)-1-substituted-ethyl)acetamides: A Novel Series of Potent and Selective K-Opiod Agonists”,Journal of Medicinal Chemistry, 34(11), (Nov. 1991),3149-3158.
Bertalmio, A. J., et al., “Differentiation Between Mu and Kappa Receptor-Mediated Effects in Opioid Drug Discrimination: Apparent pA2 Analysis”,The Journal of Pharmacology and Experimental Therapeutics, 243 (2), (Nov. 1987),591-597.
Birch, P. J., et al., “Preparation and Evaluation of Some Hydriphilic Phenylacetyl-peperazines as Peripheraly Selective k-Opiod Agonists”,Bioorganic&Medicinal Chemistry Letters, 2, (1992),1275-1278.
Botros, S. , et al., “Opioid Agonist and Antagonist Activities of Peripherally Selective Derivatives of Naltrexamine and Oxymorphamine.”,Journal of Medicinal Chemistry, 32(9), (Sep. 1989),2068-2071.
Brown, D. R., et al., “The Use of Quarternary Narcotic Antagonists in Opiate Research.”,Neuropharmacology, 24(3), (Mar. 1985),181-191.
Chang, An-Chih , et al., “Arylacetamide-Derived Fluorescent Probes: Synthesis, Biological Evaluation, and Direct Fluorescent Labeling of k Opioid Receptors in Mouse Microglial Cells”,Journal of Medicinal Chemistry, 39(8), (Apr. 12, 1996),1729-1735.
Chang, An-Chih , et al., “k Opioid receptor selective affinity labels: electrophilic benzeneacetamides as k-selective opioid antagonists”,Journal of Medicinal Chemistry, 37(26), (Dec. 23, 1994),4490-4498.
Costello, G. F., et al., “2-(3,4-Dichlorophenyl)-N-methyl-N-(2-(1-pyrrolidinyl)-1-substituted-ethyl)actamides: The Use of Conformational Analysis in the Development of a Novel Series of Opioid K Agonists”,Journal of Medicinal Chemistry, 34(1), (Jan. 1991),181-189.
Dhawan, B. N., et al., “Classification of Opioid Receptors”,Pharmacological Reviews, 48(4), (Dec. 1996),567-583.
Drower, Edward J., et al., “Selective Antagonism by Naltrindole of the Antinociceptive Effects of the Delta Opioid Agonist Cyclic (D-Penicillamine2-D-Penicillamine5) Enkephalin in the Rat.”,The Journal of Pharmacology and Experimental Therapeutics, 259, (1991),725-731.
Erez, M. , et al., “Narcotic Antagonist Potency of Bivalent Ligands which Contain B-Naltrexamine. Evidence for Bridging Between Proximal Recognition Sites.”,Journal of Medicinal Chemistry, 25(7), (Jul. 1982),847-849.
Hjorth, S. A., et al., “Analysis of Selective Binding Epitopes for the Kappa Opioid Receptor Antagonist Nor-Binaltorphimine”,Molecular Pharmacology, 47(6), (Jun. 1995),1089-1094.
Jaffe, Jerome H., et al., “Opioid Analgesics and Antagonists”,The Pharmacological Basis of Therapeutics, Eighth Edition, A.G. Gilman et al., (Eds.) Peragomon Press, New York,(1990),485-521.
Jones, R. M., et al., “5′-Guanidinonaltrindole, a highly selective and potent—opioid receptor antagonist”,European Journal of Pharmacology, 396(1), (May 12, 2000),49-52.
Jones, R. M., et al., “k-Opioid Receptors: recent advances and implications for drug design”,Curr. Opin. Drug Discuss. Dev., 1, (1998),175-182.
Jones, Robert M., et al., “Mutational Evidence for a Common k Antagonist binding packet in the wild-type k and mutant u[k303e] opioid receptors”,Journal of Medicinal Chemistry, 41(25), (Dec. 3, 1998),4911-4914.
Kataoka, H. , “Novel Indolomorphinan Derivatives.”,Chemical Abstracts, 73, Abstract No. 120798v,(1970),398.
Linner, K. M., et al., “The Delta-opioid receptor antagonist, 7-benzylspiroindanylnaltrexone, prolongs renal allograft survival in a rat model”,European Journal of Pharmacology, 354(1), (Dec. 11, 1998),R3-R5.
Linney, I. D., et al., “Design, Synthesis, and Structure-Activity Relationships of Novel Non-Imidazole Histamine H3 Receptor Antagonists”,Journal of Medicinal Chemistry, 43(12), (Jun. 15, 2000),2362-2370.
Martin, W. R., “Pharmacology of Opioids”,Pharmacological Reviews, 35, (1984),283-323.
Olmsted, S. L., et al., “A Remarkable Change of Opioid Receptor Selectivity on the Attachment of a Peptidomimetic K Address Element to the Antagonist, Natrindole: 5′-(N-Alkylamidino) methyl) naltrindole Derivatives as a Novel Class of K Opioid Receptor Antagonists.”,Journal of Medicinal Chemistry, 36(1), (Jan. 8, 1993),179-180.
Portoghese, Philip S., et al., “A Novel Opioid Receptor Site Directed Alkylating Agent with Irreversible Narcotic Antagonistic and Reversible Agonistic Activities.”,Journal of Medicinal Chemistry, 23(3), (Mar. 1980),233-234.
Portoghese, Philip S., et al., “Application of the Message-Address Concept in the Design of Highly Potent and Selective Non-Peptide Opioid Receptor Antagonists.”,Journal of Medicinal Chemistry, 31, (Feb. 1988),281-282.
Portoghese, Philip S., et al., “Bimorphinans as High Selective, Potent k Opioid Antagonists”,Journal of Medicinal Chemistry, 30(2), (1987),238-239.
Portoghese, Philip S., et al., “Binaltorphimine and Norbinaltorphimine, Pote
Jones Robert M.
Portoghese Philip S.
Sharma Shiv K.
Owens Amelia A.
Regents of the University of Minnesota
Viksnins Harris & Padys PLLP
LandOfFree
Therapeutic compounds and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic compounds and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic compounds and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3834944